This week in drug discovery (24-28 April)

News round-up for 24-28 April by DDW Digital Content Editor Diana Spencer.

Each of our top five stories this week exemplify the scientific curiosity that fuels the drug discovery sector, ultimately leading to better treatments for patients. The stories cover the efforts by research teams to discover innovative novel drugs for geographic atrophy, HIV, lung cancer, anxiety and diabetes.

The top five:

Partners use AI tools to advance novel drugs for geographic atrophy

A partnership between RetinAI Medical and Boehringer Ingelheim aims to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases.

Researchers hope to cure HIV using CAR-T cells

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy.

Macrophages suppress natural killer cells in lung cancer tumours

Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated in a preclinical study a potential new therapeutic approach to treating the most common form of lung cancer.

Discovery represents the ‘first step’ to better anti-anxiety drugs

A team of scientists have discovered that modification of a gene in the brain can reduce anxiety levels, offering an exciting novel drug target for anxiety disorders.

Tiziana develops intranasal antibody for type 1 diabetes

Biotechnology company Tiziana Life Sciences is initiating a programme to develop intranasal foralumab for the treatment or prevention of type 1 diabetes.

Suggested Reading

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free